Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation

Tea Pemovska, Eric Johnson, Mika Kontro, Gretchen A. Repasky, Jeffrey Chen, Peter Wells, Ciaran N. Cronin, Michele McTigue, Olli Kallioniemi, Kimmo Porkka, Brion W. Murray, Krister Wennerberg

Research output: Contribution to journalArticleScientificpeer-review

Original languageEnglish
JournalNature
Volume519
Issue number7541
Pages (from-to)102-U225
Number of pages13
ISSN0028-0836
DOIs
Publication statusPublished - 5 Mar 2015
MoE publication typeA1 Journal article-refereed

Fields of Science

  • CHRONIC MYELOID-LEUKEMIA
  • PATIENTS RECEIVING IMATINIB
  • BCR-ABL INHIBITOR
  • KINASE INHIBITOR
  • TYROSINE KINASE
  • POSITIVE LEUKEMIA
  • T315I MUTANT
  • FOLLOW-UP
  • RESISTANCE
  • MECHANISM
  • 3121 Internal medicine

Cite this

Pemovska, Tea ; Johnson, Eric ; Kontro, Mika ; Repasky, Gretchen A. ; Chen, Jeffrey ; Wells, Peter ; Cronin, Ciaran N. ; McTigue, Michele ; Kallioniemi, Olli ; Porkka, Kimmo ; Murray, Brion W. ; Wennerberg, Krister. / Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. In: Nature. 2015 ; Vol. 519, No. 7541. pp. 102-U225.
@article{376a759920544b09b876238a5a273469,
title = "Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation",
keywords = "CHRONIC MYELOID-LEUKEMIA, PATIENTS RECEIVING IMATINIB, BCR-ABL INHIBITOR, KINASE INHIBITOR, TYROSINE KINASE, POSITIVE LEUKEMIA, T315I MUTANT, FOLLOW-UP, RESISTANCE, MECHANISM, 3121 Internal medicine",
author = "Tea Pemovska and Eric Johnson and Mika Kontro and Repasky, {Gretchen A.} and Jeffrey Chen and Peter Wells and Cronin, {Ciaran N.} and Michele McTigue and Olli Kallioniemi and Kimmo Porkka and Murray, {Brion W.} and Krister Wennerberg",
year = "2015",
month = "3",
day = "5",
doi = "10.1038/nature14119",
language = "English",
volume = "519",
pages = "102--U225",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "7541",

}

Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. / Pemovska, Tea; Johnson, Eric; Kontro, Mika; Repasky, Gretchen A.; Chen, Jeffrey; Wells, Peter; Cronin, Ciaran N.; McTigue, Michele; Kallioniemi, Olli; Porkka, Kimmo; Murray, Brion W.; Wennerberg, Krister.

In: Nature, Vol. 519, No. 7541, 05.03.2015, p. 102-U225.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation

AU - Pemovska, Tea

AU - Johnson, Eric

AU - Kontro, Mika

AU - Repasky, Gretchen A.

AU - Chen, Jeffrey

AU - Wells, Peter

AU - Cronin, Ciaran N.

AU - McTigue, Michele

AU - Kallioniemi, Olli

AU - Porkka, Kimmo

AU - Murray, Brion W.

AU - Wennerberg, Krister

PY - 2015/3/5

Y1 - 2015/3/5

KW - CHRONIC MYELOID-LEUKEMIA

KW - PATIENTS RECEIVING IMATINIB

KW - BCR-ABL INHIBITOR

KW - KINASE INHIBITOR

KW - TYROSINE KINASE

KW - POSITIVE LEUKEMIA

KW - T315I MUTANT

KW - FOLLOW-UP

KW - RESISTANCE

KW - MECHANISM

KW - 3121 Internal medicine

U2 - 10.1038/nature14119

DO - 10.1038/nature14119

M3 - Article

VL - 519

SP - 102-U225

JO - Nature

JF - Nature

SN - 0028-0836

IS - 7541

ER -